Pemvidutide
GLP-1/GCG · s.c. · Altimmune
Summary
- Also known as
- ALT-801
- Mechanism
- GLP-1/GCG
- Route
- s.c.
- Company
- Altimmune
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 PERFORMA in MASH recruiting since Jul 2026; phase 2 MOMENTUM (obesity) and IMPACT (MASH) complete verify
- Next milestone
- PERFORMA results (primary completion Dec 2028)
Sources for the status
- Altimmune, Inc.. A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) (PERFORMA). ClinicalTrials.gov identifier NCT07795164. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07795164
- Altimmune, Inc.. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial). ClinicalTrials.gov identifier NCT05295875. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05295875
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 1 phase 2 / signal | Phase 2 (MOMENTUM) | |
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 2 phase 3 ongoing | Phase 2b IMPACT: MASH resolution met, fibrosis improvement not met at 24 weeks (Lancet 2025); phase 3 PERFORMA recruiting | PERFORMA; IMPACT 24 weeks, Lancet 2025; IMPACT 48 weeks, Lancet Gastroenterol Hepatol 2026 |
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOMENTUM | pemvidutide 2.4 mg | obesity | 48 | 391 | — | —−15.6 % vs −2.2 % estimand not specified | — | 19.6 vs 6.2 | — | 51.5 vs 11.3 | 27.8 vs 3.1 | — | −4.6 vs +3.5 | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (5)
- pemvidutide 2.4 mg · ae_dc · Summary of Safety and Tolerability table: Placebo (N=97) | 1
All AEs leading to discontinuation N (%) | 6 (6.2%) | 5 (5.1%) | 19 (19.2%) | 19 (19.6%)
- pemvidutide 2.4 mg · nausea · Summary of Safety and Tolerability table: Placebo (N=97) | 1
Nausea N (%) | 11 (11.3%) | 25 (25.5%) | 59 (59.6%) | 50 (51.5%)
- pemvidutide 2.4 mg · vomiting · Summary of Safety and Tolerability table: Placebo (N=97) | 1
Vomiting N (%) | 3 (3.1%) | 6 (6.1%) | 27 (27.3%) | 27 (27.8%)
- pemvidutide 2.4 mg · sbp · Blood Pressure and Heart Rate table
Blood Pressure and Heart Rate | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Systolic BP mm Hg, LSM (SE) | +3.5 (2.3) | -2.3 (2.2) | -1.6 (2.2) | -4.6 (2.3)
- pemvidutide 2.4 mg · weight_unsp · Summary of Efficacy Findings
Primary Endpoint: Body weight | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Body weight, all subjects, %, LSM (SE) [1 MMRM] | -2.2 (1.4) | -10.3 (1.4)*** | -11.2 (1.4)*** | -15.6 (1.4)***
Outcome trials
Other indications
IMPACT Pemvidutide · MASH F2–F3 · 24 weeks · n = 212 abstract
MASH resolution without worsening of fibrosis +38 / +32 percentage points vs placebo at 24 weeks (1.2 / 1.8 mg); fibrosis improvement +5 / +8, not significant. At 48 weeks (no biopsy): liver fat −37.1 / −46.5 percentage points vs placebo.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis 1.2 mg week 24 | +58.0 | +20.0 | +38.0 (+21.0 to +56.0) percentage points | abstract |
| MASH resolution without worsening of fibrosis 1.8 mg week 24 | +52.0 | +20.0 | +32.0 (+19.0 to +46.0) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of MASH 1.2 mg week 24 | +33.0 | +28.0 | +5.0 (−13.0 to +22.0) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of MASH 1.8 mg week 24 | +36.0 | +28.0 | +8.0 (−6.0 to +22.0) percentage points | abstract |
Verbatim quotes (4)
- MASH resolution without worsening of fibrosis
MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
- MASH resolution without worsening of fibrosis
MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
- Fibrosis improvement (≥1 stage) without worsening of MASH
Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)
- Fibrosis improvement (≥1 stage) without worsening of MASH
Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| PERFORMA Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | MASH | Phase 3 | recruiting | 2026-07 → 2028-12 | 1800 | recruiting | NCT07795164 |
| RESTORE TRIAL RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Other | Phase 2 | active not recruiting | 2025-06 → 2027-09 | 121 | active not recruiting | NCT07009860 |
| RECLAIM STUDY RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | Addiction | Phase 2 | completed | 2025-05 → 2026-07 | 100 | Completed; results not in the atlas yet | NCT06987513 |
| IMPACT IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | CV outcomes | Phase 2 | completed | 2023-07 → 2025-11 | 212 | Completed; results not yet public | NCT05989711 |
Primary sources
- Altimmune, Inc.. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial). ClinicalTrials.gov identifier NCT05295875. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05295875
- Altimmune, Inc. Altimmune announces positive topline results from MOMENTUM 48-week phase 2 obesity trial of pemvidutide [press release, Form 8-K Exhibit 99.1]. Gaithersburg (MD): Altimmune; 2023 Nov 30. Available from: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130xex99d1.htm. Available from: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130xex99d1.htm
- Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406(10520):2644-2655. PMID: 41237796.
- Noureddin M, Alkhouri N, Loomba R, Chalasani N, Sheikh MY, Tomah S, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet Gastroenterol Hepatol. 2026. PMID: 43014327.
- Altimmune, Inc.. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT). ClinicalTrials.gov identifier NCT05989711. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05989711
How to cite this page
Cite the primary publication for any single result; every value above links to it.